First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer | Zendy

Leora Horn | Zendy; Aaron S. Mansfield | Zendy; Aleksandra Szczęsna | Zendy; Libor Havel | Zendy; Maciej Krzakowski | Zendy; Maximilian J. Hochmair | Zendy; Florian Huemer | Zendy; György Losonczy | Zendy; Melissa L. Johnson | Zendy; Makoto Nishio | Zendy; Martin Reck | Zendy; Tony Mok | Zendy; Sivuonthanh Lam | Zendy; David S. Shames | Zendy; Juan Liu | Zendy; Beiying Ding | Zendy; Ariel López-Chávez | Zendy; Fairooz F. Kabbinavar | Zendy; Wei Lin | Zendy; Alan Sandler | Zendy; Stephen V. Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Author(s) -

Leora Horn,

Aaron S. Mansfield,

Aleksandra Szczęsna,

Libor Havel,

Maciej Krzakowski,

Maximilian J. Hochmair,

Florian Huemer,

György Losonczy,

Melissa L. Johnson,

Makoto Nishio,

Martin Reck,

Tony Mok,

Sivuonthanh Lam,

David S. Shames,

Juan Liu,

Beiying Ding,

Ariel López-Chávez,

Fairooz F. Kabbinavar,

Wei Lin,

Alan Sandler,

Stephen V. Liu

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1809064

Subject(s) - atezolizumab , chemotherapy , lung cancer , cytotoxic t cell , cancer research , programmed cell death , pd l1 , cytotoxicity , oncology , medicine , immunotherapy , cancer , biology , apoptosis , nivolumab , in vitro , biochemistry

Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research